Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.37 |
| ▸ | KDM1A | O60341 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 2/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5040996 | 1.00 | F10 (0.42) | F10ALDH1A1HDAC1KDM1ATSHR | |
| Hydrochloric Acid SCHEMBL5045198 | 0.90 | F10 (0.50) | F10ALDH1A1TSHRF2 | |
| Hydrochloric Acid SCHEMBL5045200 | 0.90 | F10 (0.50) | F10ALDH1A1TSHRF2 | |
| SCHEMBL5043984 | 0.85 | ALDH1A1 (0.42) | F10ALDH1A1TSHR | |
| SCHEMBL5043979 | 0.85 | ALDH1A1 (0.42) | F10ALDH1A1TSHR | |
| SCHEMBL5038160 | 0.81 | F10 (0.34) | F10ALDH1A1HDAC1KLKB1PPARG | |
| SCHEMBL5038164 | 0.81 | F10 (0.34) | F10ALDH1A1HDAC1KLKB1PPARG | |
| SCHEMBL5037578 | 0.79 | F10 (0.65) | F10ALDH1A1HDAC1TSHRKLKB1 | |
| SCHEMBL5037580 | 0.79 | F10 (0.65) | F10ALDH1A1HDAC1TSHRKLKB1 | |
| SCHEMBL5042081 | 0.78 | F10 (0.33) | F10ALDH1A1KLKB1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | F10 8/4885ALDH1A1 519/4885HDAC1 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.